Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Héctor Miguel Vetulli"'
Autor:
Rodolfo Pedro Rothlin, Mariano Duarte, Facundo Germán Pelorosso, Liliana Nicolosi, M. Victoria Salgado, Héctor Miguel Vetulli, Eduardo Spitzer
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
COVID-19 pandemic demands a swift response to find therapeutic tools that effectively reduce morbidity and mortality. Despite initial fears, evidence from retrospective observational studies supports the inhibition of the renin-angiotensin system as
Externí odkaz:
https://doaj.org/article/d030dc5a96114dda81f6b2cd93adc81a
Autor:
Francisco Azzato, Ignacio Fernandez Criado, Javier Coyle, Analia Aquieri, Marcela Castro, Héctor Miguel Vetulli, María C. Rubio, Ignacio Davolos, Liliana N. Nicolosi, Rosana Gregori, Facundo Germán Pelorosso, Pedro Mastrodonato, Sergio Sarquis, Fernando Wahlmann, Rodolfo Pedro Rothlin, Mariano Duarte, M. Victoria Salgado
Publikováno v:
EClinicalMedicine
EClinicalMedicine, Vol 37, Iss, Pp 100962-(2021)
EClinicalMedicine, Vol 37, Iss, Pp 100962-(2021)
Background Angiotensin receptor blockers (ARBs), such as telmisartan, have been postulated to treat Covid-19-induced lung inflammation. Methods This is a parallel-group, randomized, two-arm, open-label, adaptive, multicenter superiority trial with 1:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcd1279b99c1996c97eae81ee1011a75
http://europepmc.org/articles/PMC8225700
http://europepmc.org/articles/PMC8225700
Publikováno v:
Drug Development Research
In late 2019, a new coronavirus emerged in Wuhan Province, China, causing lung complications similar to those produced by the SARS coronavirus in the 2002–2003 epidemic. This new disease was named COVID‐19 and the causative virus SARS‐CoV‐2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::644f60e2a911548900e8c53ad375867b
https://doi.org/10.1002/ddr.21679
https://doi.org/10.1002/ddr.21679